ACM
CSTL icon

Advisors Capital Management’s Castle Biosciences CSTL Stock Holding History

Advisors Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.1M Sell
248,376
-2,301
-0.9% -$75.4K 0.07% 193
2025
Q4 		$9.75M Sell
250,677
-3,523
-1% -$114K 0.11% 173
2025
Q3 		$5.79M Buy
254,200
+8,333
+3% +$169K 0.07% 193
2025
Q2 		$5.02M Buy
245,867
+44,180
+22% +$818K 0.07% 194
2025
Q1 		$4.04M Buy
201,687
+22,752
+13% +$563K 0.06% 207
2024
Q4 		$4.77M Buy
178,935
+11,008
+7% +$335K 0.08% 195
2024
Q3 		$4.79M Buy
167,927
+25,626
+18% +$652K 0.08% 191
2024
Q2 		$3.1M Buy
142,301
+1,186
+0.8% +$26.4K 0.05% 220
2024
Q1 		$3.13M Buy
141,115
+19,226
+16% +$418K 0.06% 219
2023
Q4 		$2.63M Buy
121,889
+4,999
+4% +$88K 0.05% 229
2023
Q3 		$1.97M Buy
116,890
+37,318
+47% +$653K 0.05% 226
2023
Q2 		$1.09M Buy
79,572
+48,513
+156% +$983K 0.03% 253
2023
Q1 		$706K Sell
31,059
-152
-0.5% -$3.71K 0.02% 265
2022
Q4 		$735K Buy
31,211
+4,316
+16% +$100K 0.02% 265
2022
Q3 		$607K Buy
26,895
+1,678
+7% +$47K 0.02% 299
2022
Q2 		$554K Buy
25,217
+7,587
+43% +$176K 0.02% 292
2022
Q1 		$791K Buy
17,630
+617
+4% +$25.5K 0.02% 264
2021
Q4 		$729K Buy
17,013
+2,901
+21% +$152K 0.02% 288
2021
Q3 		$938K Buy
14,112
+3,253
+30% +$229K 0.03% 245
2021
Q2 		$796K Buy
+10,859
New +$717K 0.03% 254

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisors Capital Management's CSTL Position: Q1 2026 in Review

Advisors Capital Management reduced its Castle Biosciences (CSTL) stake by 0.92% in Q1 2026, selling an estimated $75.4K and leaving 248,376 shares worth $6.1M. The position accounts for 0.07% of the portfolio, ranked #193.

Advisors Capital Management first reported a position in CSTL in Q2 2021 and has held it in 20 quarters since. The position peaked at $9.75M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Advisors Capital Management held 248,376 shares of Castle Biosciences worth $6.1M as of Q1 2026.
  • Advisors Capital Management sold 2,301 Castle Biosciences shares in Q1 2026, an estimated $75.4K.
  • Castle Biosciences made up 0.07% of Advisors Capital Management's portfolio in Q1 2026, its #193 holding.
  • Advisors Capital Management first reported a position in Castle Biosciences in Q2 2021 and has held it in 20 quarters since.
  • Advisors Capital Management's Castle Biosciences position peaked at $9.75M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Advisors Capital Management's 13F filing for Q1 2026, filed 1 May 2026.